Browse All

Current Filters

CLEAR FILTER x

TITLE

Characterization of Neurological Biomarkers in Patients with Early Relapsing Multiple Sclerosis and Comparison to Healthy Controls: Year 1 Interim Analysis of the ENLIGHTEN Study of Ozanimod

Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis